Ricevi le ultime notizie sulle azioni Fortress Biotech con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di FBIOP

Ultime notizie per

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech Inc

Press Releases

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

General

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

Earnings

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

News

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Health Care

Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

Financing

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing

CKPT

DERM

FBIO

FBIOP

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

BriaCell Therapeutics Corp. - Common Shares

BriaCell Therapeutics

Boundless Bio

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Enlivex Therapeutics Ltd. - Ordinary Shares

Enlivex Therapeutics

Fortress Biotech

FibroBiologics

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

Kairos Pharma

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Kezar Life Sciences

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Moleculin Biotech

MetaVia

Nanoviricides

NeuroSense Therapeutics Ltd. - Ordinary Shares

NeuroSense Therapeutics

Passage Bio

ProMIS Neurosciences Inc. - Common Shares

ProMIS Neurosciences

Propanc Biopharma

Q32 Bio

Rallybio

Rein Therapeutics

Exicure

XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock

Comments

Fortress Biotech Notizie sulle azioni

Notizie

Ultime notizie per

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO